deltatrials
Completed PHASE3 NCT00032799

Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease

A Phase 3 International, Multicenter, Double-blind, Placebo-controlled Study of the Safety, Efficacy, and Tolerability of Intravenous Antegren (Natalizumab) in Subjects With Moderate to Severely Active Crohn's Disease

Sponsor: Biogen

Conditions Crohn's Disease
Interventions natalizumab
Updated 5 times since 2017 Last updated: Jun 14, 2016 Started: Dec 31, 2001 Primary completion: Sep 30, 2003 Completion: Sep 30, 2003

This PHASE3 trial investigates Crohn's Disease and is currently completed. Biogen leads this study, which shows 5 recorded versions since 2001 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Dec 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Biogen
  • Elan Pharmaceuticals
Data source: Biogen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • San Diego, United States